-
AffaMed Therapeutics' joint venture company settled in Beijing
Time of Update: 2021-11-15
The newly established Aichen Medical will further promote the development, production and sales of innovative high-quality intraocular lens ("IOL") products in the Greater China market .
-
Zheng·Xie Sanming's experience promotes medical improvement into the "deep water area" Internet diagnosis and treatment: prohibiting unified prescriptions and supplements
Time of Update: 2021-11-15
After the holiday, Henan Province issued the "Notice on Announcement of the Results of Centralized Purchase of Drugs in the Central Area Alliance of Henan Province", 8 varieties and 12 product specifications were selected, and 6 varieties including ranitidine injection and niacin injection were passed .
-
The domestic PD-1 annual fee may fall below 30,000? Small molecule inhibitors may fall into a price melee! Where is the way out for sky-high drugs? 2021 Medical Insurance Negotiation Outlook
Time of Update: 2021-11-15
In the field of small molecule kinase inhibitors, Soochow Securities predicts that the price reduction of Iris Vometinib may reach 75% this time, and the annual treatment fee will be reduced from 417,000 yuan to about 100,000 yuan .
-
Holding 3 clinical approval documents in hand, participating in the formulation of US Pharmacopoeia industry standards... Triassic opens a new era of 3D printing drugs
Time of Update: 2021-11-15
0 era opening strategy: through opening up technical resources, establishing a relationship with global pharmaceutical companies To realize the commercialization of 3D printing drug technology .
-
Dosing once every six months!
Time of Update: 2021-11-15
It only needs to be administered once every six months to help patients with nAMD maintain their vision From: Roche official website Neovascular AMD is a potentially blinding disease that requires eye injections once a month .
-
FDA persuades Agenus to withdraw, PD-1 is getting more and more difficult to market in the United States
Time of Update: 2021-11-15
Earlier, drugs O and K have passed accelerated drug approval for the treatment of metastatic small cell lung cancer, but due to poor efficacy data in the past two years, they were dismissed by the FDA .
-
What are the investment opportunities in the medical insurance negotiations in 2021?
Time of Update: 2021-11-15
Looking back on the past three years, medical insurance negotiations have achieved excellent results, including more than 200 new varieties, and through negotiations, the price of drugs has been greatly reduced, and the availability of drugs has been improved .
-
Interpretation of "In Vitro Diagnostic Reagent Classification Rules"
Time of Update: 2021-11-15
" Articles 8 and 9 are based on the new "Regulations" and "In Vitro Diagnostic Reagent Registration and Filing Management Measures", with reference to Order 15, clarifying the formulation and adjustment of the in vitro diagnostic reagent classification catalog and the confirmation of newly developed product categories .
-
Wang Yongjun's team CHANCE-2 climbs to the top of NEJM to guide new strategies for secondary stroke prevention Interview with authors
Time of Update: 2021-11-15
On October 28, 2021, the New England Journal of Medicine (NEJM) published online the CHANCE-2 study results of Professor Wang Yongjun’s team from Beijing Tiantan Hospital, Capital Medical University In patients with CYP2C19 inactivated alleles, ticagrelor combined with aspirin is more effective than clopidogrel combined with aspirin in preventing stroke recurrence.
-
The development of new coronavirus pneumonia vaccines and therapeutic drugs
Time of Update: 2021-11-15
According to the Cortellis database, as of September 26, 2021, there are hundreds of new coronary pneumonia neutralizing antibody drugs under research worldwide, and 23 are in the clinical development stage (Table 2) .
-
Merck's new crown oral drug will soon be approved by the European Union
Time of Update: 2021-11-15
Merck's oral new crown treatment drug Molnupiravir (Molnupiravir) The European Medicines Agency stated that the decision to initiate the rolling review was based on preliminary results of laboratory and clinical studies .
-
With the advent of gene therapy era, how can the most expensive therapy get medical insurance?
Time of Update: 2021-11-15
In May 2019, the Japan Central Social Insurance Medical Council approved the inclusion of CAR-T cell therapy product Kymriah in medical insurance, with a price of approximately 33.
-
Zejing Pharmaceuticals: Donafinil has sales of nearly 100 million yuan in more than 100 days, and the company's commercialization capabilities have been initially verified by the market
Time of Update: 2021-11-15
Zejing Pharmaceuticals said that the company is vigorously promoting Donafinil to enter various guides and insurance catalogs, which is expected to benefit more liver cancer patients .
-
The 2021 Hurun Report is released!
Time of Update: 2021-11-15
78%; the net profit attributable to shareholders of listed companies was 722 million yuan, a year-on-year increase of 195.
48%; net profit attributable to parent company was 888 million yuan, a year-on-year increase of 2.
-
A new breakthrough in first-line cholangiocarcinoma!
Time of Update: 2021-11-15
On October 25th, AstraZeneca announced that its PD-L1 monoclonal antibody duvalizumab (Imfinzi) combined with chemotherapy for the first-line treatment of advanced biliary tract cancer (BTC) in Phase III clinical TOPAZ-1 achieved overall survival in the interim analysis The primary end point of the period (OS) .
-
Internet diagnosis and treatment prohibits unified prescriptions and supplements!
Time of Update: 2021-11-15
The draft opinion clarifies that medical institutions should strictly abide by prescription management regulations such as the "Prescription Management Measures" when carrying out Internet diagnosis and treatment activities, strengthen drug management, and prohibit problems such as unified prescriptions and supplements .
-
The revival of therapeutic tumor vaccines! What are the results of the clinical trials of the mRNA vaccine giants?
Time of Update: 2021-11-15
Vaccines against human papillomavirus (HPV) and hepatitis B virus have been successfully applied to the prevention of related tumors . In contrast, the development of therapeutic tumor vaccines is
-
Sintilimab sold for 800 million yuan in the third quarter. Medical insurance negotiations are about to start
Time of Update: 2021-11-15
Cinda’s three first-line indications are expected to enter the medical insurance negotiations this year, targeting squamous, non-squamous NSCLC and hepatocellular carcinoma (HCC); Baekje’s new negotiated indications also include first-line NSCLC, as well as second-line and above HCC .
-
Aiming at the ultra-small CRISPR gene editing system Vertex for nearly 700 million U.S. dollars to re-layout
Time of Update: 2021-11-15
On October 26, 2021, Vertex Pharmaceuticals and Mammoth Biosciences announced a new collaboration to use Mammoth's ultra-small CRISPR system to develop in vivo gene editing therapies for the treatment of two genetic diseases .
-
Heavy starting!
Time of Update: 2021-11-15
In 2020, STEM in Chinese hospitals will continue to use unified standards, sources, and methods to build an evaluation system from the three dimensions of scientific and technological output, academic impact, and scientific and technological conditions .
